Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients

J Am Acad Dermatol. 2017 Jun;76(6):1189-1191. doi: 10.1016/j.jaad.2017.02.026.

Authors

Patrizia Weber¹, S Morteza Seyed Jafari², Nikhil Yawalkar¹, Robert E Hunger¹

Affiliations

¹ Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.
² Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland. Electronic address: seyedjafarism@yahoo.com.

PMID: 28522043
DOI: 10.1016/j.jaad.2017.02.026

No abstract available

MeSH terms

Administration, Oral
Adult
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Hidradenitis Suppurativa / diagnosis*
Hidradenitis Suppurativa / drug therapy*
Hidradenitis Suppurativa / psychology
Humans
Male
Middle Aged
Quality of Life*
Sampling Studies
Severity of Illness Index
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Thalidomide
apremilast